New rapid COVID-19 test the result of university-industry partnership

Innovative platform pairs mass spectrometry with machine learning
UC Davis Health
26-Apr-2021 3:25 PM EDT, by UC Davis Health

Newswise — (SACRAMENTO) — A partnership between UC Davis and Maurice J. Gallagher, Jr., chairman and CEO of Allegiant Travel Company, has led to a new rapid COVID-19 test.

A recent study published Nature Scientific Reports shows the novel method to be 98.3% accurate for positive COVID-19 tests and 96% for negative tests.  

“This test was made from the ground up,” said Nam Tran, lead author for the study and a professor of pathology in the UC Davis School of Medicine. “Nothing like this test ever existed. We were starting with a clean slate.” 

The novel COVID-19 test uses an analytical instrument known as a mass spectrometer, which is paired with a powerful machine-learning platform to detect SARS-CoV-2 in nasal swabs. The mass spectrometer can analyze samples in minutes, with the entire process taking a total of about 20 minutes.

The accuracy matches or outperforms many of the current COVID-19 screening tests. The new testing method may allow for the rapid screening of large numbers of individuals for businesses, schools, venues and other large facilities.  

The project originated with Gallagher, a UC Davis alumnus and a longtime supporter of innovation and entrepreneurship at UC Davis.  

Last year, when the pandemic brought the airline and hospitality industries almost to a standstill, he began conceptualizing approaches that would allow people to gather again safely.  

Gallagher approached H. Rao Unnava, professor and dean of the UC Davis Graduate School of Management, who connected him with Tran at the School of Medicine.  

Gallagher and UC Davis entered into a Sponsored Research Agreement, with support from Shimadzu Scientific Instruments, to develop an automated COVID-19 test on a mass spectrometer.  

Mass spectrometers are essential analytic tools used by a wide variety of industries for research and testing.  

This is the first test for COVID-19 that pairs mass spectrometry with robotics and a robust automated machine learning platform to rapidly deliver test results. The coupling of these unique elements not only allows testing for COVID-19 but may be able to quickly adapt to detect other diseases and perhaps future pandemic organisms. 

“Mr. Gallagher, through his generosity as an alum, has shown how business and universities can work together in solving problems of critical importance to the world,” said Unnava. “I am glad that this groundbreaking work will continue to build on the reputation of UC Davis as a place where you always ‘Expect Greater.’”  

Project builds on the prior success of MILO platform 

The collaboration is part of a new center in the School of Medicine, the UC Davis Center for Diagnostic Innovation.  

“This game-changing, rapid new COVID-19 test speaks to the deep expertise of our faculty and scientists to find novel solutions to pressing global health challenges,” said Allison Brashear, dean of the UC Davis School of Medicine. “It’s this kind of innovation and collaboration that has been the hallmark of our response to the pandemic.”  

To ensure support for the study’s analytic portion, Tran enlisted Hooman Rashidi, a longtime collaborator and a professor in the Department of Pathology and Laboratory Medicine. 

The machine, a mass spectrometer MALDI-TOF, or matrix-assisted laser desorption/ionization time-of-flight, uses a laser to create small particles — ions — from large molecules in the testing sample. These ionized particles create signals that can be used to identify many compounds, including those associated with microorganisms and pathogens.   

For the study, 226 nasal swabs from UC Davis’ biorepository of COVID-19 tests were ionized in the Shimadzu 8020. The swabs were from leftover samples and volunteers who consented to the study. Some of the participants had COVID-19 symptoms, and some were asymptomatic. 

The hundreds of peaks and signals produced by the ionized test swabs were analyzed by the automated machine learning platform MILO (Machine Intelligence Learning Optimizer). Machine learning is a subset of artificial intelligence, or AI. Tran, Rashidi and Samer Albahra are the co-developers of MILO. The platform has previously been used to predict severe infections and acute kidney disease.  

For the COVID-19 test, MILO finds distinguishing patterns among the many mass spectrometry peaks and signals and deciphers which patterns correspond to the presence or absence of the SARS-CoV-2 virus in the samples.  

MILO accomplished the analysis in a fraction of the time that a non-automated machine-learning approach would have taken. “This meant drastically expediting the study without compromising any performance measures,” said Rashidi. 

Gallagher has launched a new startup, SpectraPass, to develop the rapid, automated system into a means to facilitate opening businesses and the economy.  

Experts at UC Davis Health are helping guide the SpectraPass team through the scientific, machine learning and clinical steps needed to move the COVID-19 testing technology closer to emergency use authorization by the Food and Drug Administration (FDA). 

“The COVID-19 pandemic not only brought the world’s commerce and travel to a halt – it also took away our fundamental human interaction, our freedom to be together,” said Gallagher. “This project has resulted in a real breakthrough that can not only provide instant, accurate information about COVID infection, but can be an important part of addressing other viruses and even developing therapies. The excitement of working with the team at UC Davis is in knowing we are helping make sure our children and grandchildren are better equipped to deal with potential pandemics in the future.”

The partnership exemplifies the goals of Aggie Square, which brings together the university, community and industry to connect and collaborate.  

“As a top-tier research university known for its excellence and disciplinary breadth, UC Davis is exceptionally well-positioned to work with our industry partners on groundbreaking innovations that benefit society,” said Mary Croughan, provost and executive vice chancellor.

Additional authors on the study include Taylor Howard, Julia Loegering, Brett Phinney, and Michelle Salemi, University of California, Davis; Ryan Walsh, Shimadzu Scientific Instruments; and John Pepper, Allegiant Travel Company. 

 

To learn more about the rapid COVID-19 test, watch this video.

https://youtu.be/Sy2tGAVL2uU

 

Download images and video here 

SEE ORIGINAL STUDY



Filters close

Showing results

110 of 5811
Newswise:Video Embedded study-links-covid-19-public-health-efforts-to-dramatic-drop-in-copd-hospitalizations
VIDEO
Released: 14-Jun-2021 8:00 AM EDT
Study Links COVID-19 Public Health Efforts to Dramatic Drop in COPD Hospitalizations
University of Maryland Medical Center

Public health measures designed to reduce the spread of the COVID-19 virus may have fostered a substantial side benefit: A 53 percent drop in hospital admissions for chronic obstructive pulmonary disease (COPD), likely due to a drop in circulating seasonal respiratory viruses such as influenza.

access_time Embargo lifts in 2 days
Embargo will expire: 20-Jun-2021 9:00 AM EDT Released to reporters: 13-Jun-2021 12:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 20-Jun-2021 9:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: 267646_web.jpg
Released: 11-Jun-2021 2:10 PM EDT
Saliva can be more effective than nasopharyngeal swabs for COVID-19 testing
Elsevier

The collection of nasopharyngeal swab (NPS) samples for COVID-19 diagnostic testing poses challenges including exposure risk to healthcare workers and supply chain constraints.

Released: 11-Jun-2021 1:25 PM EDT
Physical Activity May Curb Health Care Worker Burnout
University of Georgia

More physical activity programming could mitigate the effects of stress and improve worker mental and emotional health.

Newswise: AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
9-Jun-2021 6:05 PM EDT
AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
University of California San Diego Health

UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.

Released: 10-Jun-2021 5:35 PM EDT
Senolíticos reducen síntomas de COVID-19 en estudios preclínicos
Mayo Clinic

Los investigadores de Mayo Clinic y sus colegas de la Universidad de Minnesota demostraron que la COVID-19 exacerba las consecuencias nocivas de las células senescentes en el cuerpo. En estudios preclínicos, los fármacos senolíticos descubiertos en Mayo redujeron considerablemente la inflamación, la enfermedad y la mortalidad debida a la infección por covid en ratones ancianos. Los resultados se publican en la revista Science.

Released: 10-Jun-2021 5:30 PM EDT
Senolíticos reduzem os sintomas de COVID-19 em estudos pré-clínicos
Mayo Clinic

Os pesquisadores da Mayo Clinic e colegas da Universidade de Minnesota mostraram que o COVID-19 intensifica o impacto prejudicial das células senescentes no corpo. Em estudos pré-clínicos, os medicamentos senolíticos descobertos na Mayo reduziram significativamente a inflamação, a gravidade da doença e a mortalidade da infecção por COVID em camundongos mais velhos. Essas conclusões foram publicadas na revista Science.

Newswise: FresnoSTateVaxImage2.jpg
Released: 10-Jun-2021 5:25 PM EDT
CSU Campuses Join COVID-19 College Vaccine Challenge
California State University (CSU) Chancellor's Office

The CSU pledges to be a Vaccine Champion University as part of new White House effort aimed at increasing vaccinations for younger Americans.

Released: 10-Jun-2021 5:05 PM EDT
الأدوية المحللة للشيخوخة تقلل من أعراض فيروس كورونا المستجد (كوفيد-19) في الدراسات ما قبل السريرية
Mayo Clinic

أظهر باحثو مايو كلينك وزملاؤهم في جامعة مينيسوتا أن فيروس كورونا المستجد (كوفيد-19) يفاقم التأثير الضار للخلايا الشائخة في الجسم. ففي الدراسات ما قبل السريرية، قللت الأدوية المحللة لالشيخوخة التي تم اكتشافها في مايو بشكل كبير من الالتهاب والمرض والوفيات الناجمة عن عَدوى فيروس كورونا المستجد في الفئران الأكبر سنًا. النتائج منشورة في مجلة ساينس.

7-Jun-2021 7:05 AM EDT
Study Examines the Effects of COVID-19 on Human Kidney Cells
American Society of Nephrology (ASN)

• The virus that causes COVID-19 can infect and replicate in human kidney cells, but this does not typically lead to cell death. • Kidney cells that already have features of injury may be more easily infected and develop additional injury.


Showing results

110 of 5811

close
1.25228